Zobrazeno 1 - 10
of 57
pro vyhledávání: ''
Autor:
George A W Bruyn, Attila Pethö-Schramm, Ed N. Griep, Michelle E A Borm, Marjolein J H de Hair, Ruth Klaasen, Maxime M A Verhoeven, Jacob M van Laar, Johannes W. J. Bijlsma, Paco M J Welsing, Janneke Tekstra, Floris P J G Lafeber, Reinhard Bos, Johannes W G Jacobs
Publikováno v:
Rheumatology (Oxford, England)
Objectives U-Act-Early was a 2-year, randomized placebo controlled, double-blind trial, in which DMARD-naïve early RA patients were treated to the target of sustained remission (SR). Two strategies initiating tocilizumab (TCZ), with and without meth
Autor:
Seiichi Yoshimoto, Hiroshi Igaki, Naoya Murakami, Takao Ueno, Kae Okuma, Kenya Kobayashi, Taisuke Mori, Kana Takahashi, Kimiteru Ito, Yoshitaka Honma, Yuko Nakayama, Jun Itami, Narikazu Boku, Hiroyuki Okamoto, Yuko Kubo, Koji Inaba
Publikováno v:
Journal of Radiation Research
Our previous study by Murakami N, Mori T, Nakamura S, Yoshimoto S, Honma Y, Ueno T, Kobayashi K, Kashihara T, Takahashi K, Inaba K, Okuma K, Igaki H, Nakayama Y, Itami J. (J Radiat Res. 2019 Jul 30. pii: rrz053. doi: 10.1093/jrr/rrz053. [Epub ahead o
Autor:
Joanne Stocks, Weiya Zhang, Monica S M Persson, Michael Doherty, Gwen Sascha Fernandes, David A. Walsh, Aliya Sarmanova
Objectives To determine individual responses to ibuprofen gel or capsaicin cream for painful, radiographic knee OA using a series of n-of-1 trials. Methods Twenty-two participants were allocated 5% ibuprofen gel (A) and 0.025% capsaicin cream (B) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f9f8f747b773d9b35a11521c327785f
Autor:
A. P. Meijs, Evert J. Waasdorp, A.J. Ploeg, Bregje J.W. Thomassen, M. B. G. Koek, Rutger-Jan Swijnenburg, A. Bosman, W. van Gijn, M.W.G.A. Bronkhorst, J.C.A. De Mol Van Otterloo, A. Charehbili, J. van den Bremer, Johannes A. Govaert, Hein Putter, C.J.H. van de Velde, P. van der Zwaal
Publikováno v:
BJS Open, Vol 4, Iss 4, Pp 731-733 (2020)
BJS Open, 3(5), 617-622
BJS Open
BJS Open, Vol 3, Iss 5, Pp 617-622 (2019)
BJS Open, 3(5), 617-622. John Wiley & Sons Ltd.
BJS Open, 3(5), 617-622
BJS Open
BJS Open, Vol 3, Iss 5, Pp 617-622 (2019)
BJS Open, 3(5), 617-622. John Wiley & Sons Ltd.
Surgical-site infection (SSI) is a serious surgical complication that can be prevented by preoperative skin disinfection. In Western European countries, preoperative disinfection is commonly performed with either chlorhexidine or iodine in an alcohol
Autor:
Sermin Toto, Dietmar Winkler, Wolfgang Huf, Siegfried Kasper, Renate Grohmann, Michaela-Elena Friedrich, Rolf R. Engel, Anastasios Konstantinidis
Publikováno v:
International Journal of Neuropsychopharmacology
Background Cardiovascular diseases are still the leading cause of global mortality. Some antipsychotic agents can show severe cardiovascular side effects and are also associated with metabolic syndrome. Methods This observational study was based on d
Autor:
Sharon Love, Pippa Corrie, S B Mohammed, V. Urbonas, M Goff, Claire Scudder, Matthew Wheater, Dirk Schadendorf, Elizabeth Ruth Plummer, Cornelia Mauch, Lisa Zimmer, Mark R. Middleton, Ernie Marshall, Sarah Danson
Publikováno v:
Annals of Oncology
Background Advanced melanoma treatments often rely on immunotherapy or targeting mutations, with few treatment options for wild-type BRAF (BRAF-wt) melanoma. However, the mitogen-activated protein kinase pathway is activated in most melanoma, includi
Autor:
Yan Guo, Hai Li, Haipeng Xiao, Xueying Chen, Sunil Pokharel, Xiaoying He, Hongyu Guan, Huasheng Yang, Yanbing Li, Yuxin Chen
Publikováno v:
The Journal of Clinical Endocrinology and Metabolism
ContextGraves’ orbitopathy (GO) causes infiltrative exophthalmos by inducing excessive proliferation, adipogenesis, and glycosaminoglycan production in orbital fibroblasts (OFs). Interference with OF autophagy is a potential therapy for proptosis.O
Autor:
Francesco P. Bernardini, Gabriela Casabona, Morris E. Hartstein, José Raúl Montes, Ilaria Baldelli, Brent Skippen
Background Chronic, long-lasting edema accompanied by the Tyndall effect as a delayed reaction to hyaluronic acid (HA) filler injection seems to occur exclusively in the eyelids. Objectives The authors sought to present a treatment algorithm for mana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8beecfcd0b997e2d6519bd9a740acdb0
https://hdl.handle.net/11567/952171
https://hdl.handle.net/11567/952171
Autor:
Corrie, PG, Marshall, A, Nathan, PD, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, CG, Marples, M, Danson, SJ, Marshall, E, Houston, SJ, Board, RE, Waterston, AM, Nobes, JP, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, PM, Ottensmeier, CH, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, EO, Harman, C, Weiss, M, Myers, KA, Chhabra, A, Rodwell, SH, Dunn, JA, Middleton, MR, AVAST-M Investigators, Nathan, P, Dziewulski, P, Holikova, S, Panwar, U, Thomas, A, Corrie, P, Sirohi, B, Kelly, C, Middleton, M, Danson, S, Lester, J, Ajaz, M, Houston, S, Board, R, Eaton, D, Waterston, A, Nobes, J, Loo, S, Gray, G, Stubbings, H, Marsden, J, Patel, P, Ottensmeier, C, Dega, R, Herbert, C, Price, C, Brunt, M, Scott-Brown, M, Hamilton, J, Hayward, RL, Smyth, J, Woodings, P, Nayak, N, Burrows, L, Wolstenholme, V, Wagstaff, J, Nicolson, M, Wilson, A, Barlow, C, Scrase, C, Podd, T, Gonzalez, M, Stewart, J, Highley, M, Grumett, S, Talbot, T, Nathan, K, Coltart, R, Gee, B
Publikováno v:
Annals of Oncology
Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A & Middleton, M R 2019, ' Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial ', Annals of Oncology, vol. 30, no. 12, pp. 2013-2014 . https://doi.org/10.1093/annonc/mdz237
Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A & Middleton, M R 2018, ' Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial ', Ann Oncol., vol. 29, no. 8, pp. 1843-1852 . https://doi.org/10.1093/annonc/mdy229
Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A & Middleton, M R 2019, ' Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial ', Annals of Oncology, vol. 30, no. 12, pp. 2013-2014 . https://doi.org/10.1093/annonc/mdz237
Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A & Middleton, M R 2018, ' Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial ', Ann Oncol., vol. 29, no. 8, pp. 1843-1852 . https://doi.org/10.1093/annonc/mdy229
Background Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurr
Autor:
Zancong Shen, Michael Gillen, Amy Yamamoto, Jesse Hall, Xiaohong Yan, Masanari Shiramoto, Yasushi Ito, Sha Liu
Publikováno v:
Rheumatology (Oxford, England)
Objectives Verinurad (RDEA3170) is a high-affinity inhibitor of the URAT1 transporter in clinical development for treating gout and asymptomatic hyperuricaemia. The aim of this Phase 2a, randomized, open-label study was to investigate the multiple-do